clinical trials as topic

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
Juliane Manitz, Sandra P D'Angelo, Andrea B Apolo, S Peter Eggleton, Marcis Bajars, Oliver Bohnsack, James L Gulley

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e003302; DOI: 10.1136/jitc-2021-003302
Immuno-oncology trends: preclinical models, biomarkers, and clinical development
Maryland Rosenfeld Franklin, Suso Platero, Kamal S Saini, Giuseppe Curigliano, Steven Anderson

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003231; DOI: 10.1136/jitc-2021-003231
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
Weixiong Yang, Xiangbin Xing, Sai-Ching Jim Yeung, Siyu Wang, Wenfang Chen, Yong Bao, Fang Wang, Shiting Feng, Fang Peng, Xiaoyan Wang, Shuling Chen, Minghui He, Ning Zhang, Honglei Wang, Bo Zeng, Zhenguo Liu, Biniam Kidane, Christopher W Seder, Kazuo Koyanagi, Yaron Shargall, Honghe Luo, Sui Peng, Chao Cheng

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003497; DOI: 10.1136/jitc-2021-003497
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
Paolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, Todd M Bauer, Marcello Tucci, Antoine Italiano, Roberto Iacovelli, Wu-Chou Su, Christophe Massard, Mansoor Saleh, Gennaro Daniele, Alastair Greystoke, Martin Gutierrez, Shubham Pant, Ying-Chun Shen, Matteo Perrino, Robin Meng, Giovanni Abbadessa, Helen Lee, Yingwen Dong, Marielle Chiron, Rui Wang, Laure Loumagne, Lucie Lépine, Johann de Bono

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003697; DOI: 10.1136/jitc-2021-003697
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M O’Malley, Vanessa Samouelian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeleit, Charles Leath III, Wei Guo, Ellie Im, Sybil Zildjian, Xinwei Han, Tao Duan, Jennifer Veneris, Bhavana Pothuri

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003777; DOI: 10.1136/jitc-2021-003777
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10⁺ advanced non-small cell lung cancer
George R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, Victor Moreno, Justin Gainor, Martin J Edelman, John V Heymach, Ramaswamy Govindan, Carlos Bachier, Bernard Doger de Spéville, Matthew J Frigault, Anthony J Olszanski, Vincent K Lam, Natalie Hyland, Jean-Marc Navenot, Svetlana Fayngerts, Zohar Wolchinsky, Robyn Broad, Dzmitry Batrakou, Melissa M Pentony, Joseph P Sanderson, Andrew Gerry, Diane Marks, Jane Bai, Tom Holdich, Elliot Norry, Paula M Fracasso

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003581; DOI: 10.1136/jitc-2021-003581
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
Osama E Rahma, Kevin Tyan, Anita Giobbie-Hurder, Andrew S Brohl, Philippe L Bedard, Daniel J Renouf, Elad Sharon, Howard Streicher, Emma Hathaway, Rachel Cunningham, Michael Manos, Mariano Severgnini, Scott Rodig, F Stephen Hodi

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003569; DOI: 10.1136/jitc-2021-003569
Imaging endpoints for clinical trial use: a RECIST perspective
Saskia Litière, Jan Bogaerts

Journal for ImmunoTherapy of Cancer Nov 2022, 10 (11) e005092; DOI: 10.1136/jitc-2022-005092
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
Marina Natoli, Klas Hatje, Pratiksha Gulati, Fabian Junker, Petra Herzig, Zhiwen Jiang, Iakov I Davydov, Markus Germann, Marta Trüb, Daniel Marbach, Adrian Zwick, Patrick Weber, Stefan Seeber, Mark Wiese, Didier Lardinois, Viola Heinzelmann-Schwarz, Robert Rosenberg, Lothar Tietze, Kirsten D Mertz, Pablo Umaña, Christian Klein, Laura Codarri-Deak, Henry Kao, Alfred Zippelius

Journal for ImmunoTherapy of Cancer Nov 2022, 10 (11) e005548; DOI: 10.1136/jitc-2022-005548
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
Aung Naing, John D Powderly, John J Nemunaitis, Jason J Luke, Aaron S Mansfield, Wells A Messersmith, Solmaz Sahebjam, Patricia M LoRusso, Ignacio Garrido-Laguna, Lance Leopold, Ryan Geschwindt, Kai Ding, Michael Smith, Jordan D Berlin

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e004223; DOI: 10.1136/jitc-2021-004223

Main menu

clinical trials as topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

clinical trials as topic

Pages